Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure | Zendy

Douglas L. Packer | Zendy; Jonathan P. Piccini | Zendy; Kristi H. Monahan | Zendy; Hussein R. AlKhalidi | Zendy; A Silverstein | Zendy; Peter A. Noseworthy | Zendy; Jeanne E. Poole | Zendy; Tristram D. Bahnson | Zendy; Kerry L. Lee | Zendy; Daniel B. Mark | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure

Author(s) -

Douglas L. Packer,

Jonathan P. Piccini,

Kristi H. Monahan,

Hussein R. AlKhalidi,

A Silverstein,

Peter A. Noseworthy,

Jeanne E. Poole,

Tristram D. Bahnson,

Kerry L. Lee,

Daniel B. Mark

Publication year - 2021

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.050991

Subject(s) - medicine , atrial fibrillation , cardiology , ablation , heart failure , drug , pharmacotherapy , pharmacology

In patients with heart failure and atrial fibrillation (AF), several clinical trials have reported improved outcomes, including freedom from AF recurrence, quality of life, and survival, with catheter ablation. This article describes the treatment-related outcomes of the AF patients with heart failure enrolled in the CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research